Address: 3F, No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C
Tel: 886-2-8170-6000
Web: http://www2.cde.org.tw/Pages/default.aspx
The Center for Drug Evaluation (CDE) was established by the Department of Health (DOH) of Taiwan on July 13, 1998 as a non-government, non-profit organization. CDE evaluates new drugs and new medical devices and provides health technology assessment for regulatory requirements commissioned by DOH. Related consultation services are offered. Furthermore, CDE develops pharmaceutical regulatory science and makes timely recommendations to meet the need of policy development. With the vision – Regulatory Science, Service for Life, CDE plays a pivotal role in enhancing the efficiency and quality of drug and device evaluation, thus promoting public health and welfare. CDE is committed to contribute to the national public health system and to ensure that the public can obtain safe, effective, and innovative drugs and devices in a timely manner.
CDE evaluates new drugs and new medical devices for regulatory requirements and offers related consultation services under the delegation and commission of DOH. Furthermore, CDE develops pharmaceutical regulatory science and makes timely recommendations to meet the need of policy development. Thus, CDE contributes to the national public health system and ensures that the public can obtain safe and effective innovative new drugs in a timely manner through the efforts of a team of full-time professionals .
In an exclusive interview, Janet Woodcock, head of the Center for Drug Evaluation and Research (CDER) at the US Food & Drug Administration (FDA) outlines how the world’s gold-standard agency…
The General Manager of OBI Pharma, a biopharmaceutical company currently working on a breast cancer drug, offers perspectives on developing a successful biotech company in Taiwan, the overall drug development…
Calvin Tsai and Jack Wu talk about their two-pronged international approach through pharmaceuticals and nutricare. The head of the nutricare business elaborates on the challenge of introducing milk products to…
A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not…
Charles Lin discusses the impact of investment in R&D on Lotus’s product line, and how this has shaped the competitive value of the company over the last decade, as well…
In Taiwan, GSK recently signed Memorandum of Understanding with the National Research Program of Biopharmaceuticals (NRPB), building on research partnerships in Taiwan that include a 2007 agreement with National Taiwan…
Dr. Wen, can you please explain the vision behind Mycenax, and the areas in which you are currently focused? Here at Mycenax, our vision is from bench to better life…
Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might…
The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this week. What are the key points to take away…
Phytohealth is a trailbalzer in the Taiwanese biotech industry: the first publically-listed biopharma company in the country, and the first company to receive NDA approval for a Botanical New Drug.…
In 2010, you began your last interview with us by mentioning two things: that because of the nature of this affiliate’s portfolio—with only 35% of revenues generated by pharma at…
Mr. Fang-Yue Lin was a Department of Health Minister before becoming Superintendent of TVGH just 7 short months ago. He shares with us his Insight to the reform of the…
Alex Ho has more than 15 years of significant pharmaceutical industry expertise, spanning across sales, marketing and product management in multinational companies. These companies include Novartis, Janssen, L’Oreal, GSK and…
See our Cookie Privacy Policy Here
